Exploring CPX351 and Its Impact on AML Treatment Strategies

Today’s podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focus on the roles of intensive chemotherapy, allogeneic stem cell transplantation, and maintenance therapies. Key topics include optimizing initial therapy to achieve deeper remissions, the benefits of using measurable residual disease (MRD) assays to tailor post-remission treatments, and exploring new maintenance options such as targeted agents.

The post Prolonging remission in AML: current approaches & future outlooks appeared first on VJHemOnc.